Member Info for Tiger16

This will close at 4 .. and then expect another big rise tomorrow .. this is the real deal .

Guys you just cant use stop losses with news of FDA approvals on cancer .. history in the making , big buy orders need filling , and they stole your shares .. this is only heading into a re rate .. simple .. this is not financial advise its common sense ...

This is a opportunity of the decade ,. its that simple ..

There is more selling going on here then buying .. The news was priced in over the weeks building up from the looks of the market reaction ..

I feel good being a part of this and it was if the gods called it ,supporting a Cancer treatment that helps make me feel good for my reasons I wont go into here , yet I hope those who need help can now access it through this drug and it wont be a long wait ..

Guys I am not going to de ramp , and I believe in the company , this is a long tern hold .. the news was expected .. Now we all know where the smart money is going today , as I dont want to be accused of ramping another share I wont be on this board ..

Ill be back here soon .. good luck all

Cont : this is going to rise like NYCT and make life changing money as well as and more importantly improve cancer treatments . This is what we are backing now . This is no rainbow chase .. it’s life changing for so many cancer patients.. well done POLB ..

🔬 What Is POLB 001 and Why Is It Important?

POLB 001 is an oral p38 MAP kinase inhibitor developed to prevent or treat Cytokine Release Syndrome (CRS), a severe and potentially life-threatening side effect that can occur in patients undergoing certain cancer immunotherapies, such as CAR-T cell therapy and bispecific antibody treatments. CRS affects over 70% of patients receiving these therapies, leading to symptoms ranging from mild flu-like effects to severe complications requiring intensive care.  

Currently, there are limited approved treatments for CRS, and no established preventative therapies. POLB 001 aims to fill this gap by offering a preventative solution, potentially improving patient outcomes and expanding the accessibility of advanced cancer immunotherapies.

⸻

💰 Market Potential

Independent research has identified a market opportunity exceeding $10 billion for POLB 001 as a preventative therapy for cancer immunotherapy-induced CRS. 

This substantial market potential is part of the broader oncology sector, which is experiencing significant growth:

• Global Oncology Market: Valued at approximately $356.20 billion in 2025, with projections to reach around $903.81 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.9%. 

• Cancer Therapy Market: Estimated at $243.67 billion in 2025, expected to grow to $403.99 billion by 2030, at a CAGR of 10.64%. 

The significant unmet need for effective CRS prevention and the expanding oncology market underscore the commercial potential of POLB 001.

⸻

📈 Significance of the FDA Orphan Drug Designation

The FDA’s Orphan Drug Designation provides several benefits that can accelerate the development and commercialization of POLB 001: 

• Market Exclusivity: Seven years of U.S. market exclusivity upon approval. 

• Financial Incentives: Eligibility for tax credits related to clinical trial costs and exemption from certain FDA fees.

• Regulatory Support: Assistance with clinical trial design and potential for expedited review processes.

These incentives not only facilitate the drug’s development but also enhance its attractiveness to potential partners and investors.

⸻

👥 Impact on Cancer Patients

By preventing CRS, POLB 001 could significantly improve the safety profile of potent cancer immunotherapies, making them more accessible to a broader patient population. This advancement has the potential to: 

• Enhance Patient Outcomes: Reducing the incidence of CRS can lead to better overall treatment experiences and outcomes for patients.

• Expand Treatment Accessibility: With a preventative solution for CRS, more patients may become eligible for advanced immunotherapies, potentially in outpatient settings.

• Alleviate Healthcare Burdens: Preventing severe CRS cases can decrease hospitalizations and associated healthcare costs.

There is no surprise here for the SP , the MM

Guys just stand by , news is incoming , they have the cash to sign of Audit , the million dolor question is what else do they have up their sleeve , hence they got the green light for millions again in investment ..

Potential of the Poolbeg Pharma (POLB) Investor Call (Thursday, 30 May 2025)

Poolbeg Pharma is holding an investor call this Thursday to discuss recent progress, including the exciting news that their lead candidate, POLB 001, has received Orphan Drug Designation (ODD) from the U.S. FDA.

Here’s what this means and why it’s important:

• 1. Regulatory milestone: Orphan Drug Designation is a special status that can accelerate a drug’s development for rare diseases, giving it extra market exclusivity and potential tax incentives in the U.S. It signals that POLB 001 is addressing an unmet need and could become more commercially viable.

• 2. Strengthened buyout potential: Big pharmaceutical companies are often interested in drugs with ODD because of the lower risk and higher potential for profits. POLB’s leadership might discuss how this development could open doors to strategic partnerships or even an acquisition.

• 3. Deeper insights for investors: This call allows investors to hear directly from Poolbeg’s leadership team. They might provide clarity on next steps for clinical trials, timelines, and how they’re managing cash and partnerships. This can help investors assess the company’s financial health and future potential.

• 4. Possible market reaction: While past performance doesn’t guarantee future results, positive updates from this call could potentially boost investor confidence and trading activity.

• 5. Access to Q&A: Attendees can submit questions and get answers from Poolbeg’s executives, providing insights that might not be available in news articles.

⸻

What to watch for in the call:

• Updates on the POLB 001 clinical trials and timelines.

• Potential discussions about licensing deals or buyout interest.

• Financial outlook — how long their cash can last without needing new funding.

• Progress on other pipeline drugs or partnerships.

Summary:

This investor call is a chance to hear from Poolbeg’s leadership directly, understand how this ODD milestone could shape the company’s future, and gather information to decide whether POLB’s shares are a good fit for your investment goals.

Disco 6 I missed the investor call you have just mentioned on thurs , could we please explian further what this means for us investors .. ??

Guys as I want all of us to make money and I have been a patriot here for some time after selling put to buy CTAI and CPAI , I have now sold out and bought POLB .

Why ?

The recent FDA Orphan Drug Designation (ODD) granted to Poolbeg Pharma’s lead candidate, POLB 001, is a significant milestone. This designation not only underscores the potential of POLB 001 in addressing a critical unmet medical need but also enhances its commercial appeal to prospective partners. The ODD status offers benefits such as seven years of market exclusivity in the U.S. upon regulatory approval, potential waiver of application fees, and eligibility for tax credits related to clinical trial costs.

When comparing Poolbeg Pharma (LSE: POLB) and ImmuPharma (LSE: IMM) regarding their positioning for a potential buyout, several factors come into play:

Poolbeg Pharma (POLB):

• Advanced Pipeline: POLB 001 is a Phase 2-ready candidate targeting Cytokine Release Syndrome (CRS), with a potential market opportunity of approximately $10 billion. 

• Strategic Acquisitions: Poolbeg has secured an exclusive 12-month option to acquire tPTX, a treatment for Behçet’s Disease, which has both Orphan Drug and Fast Track Designations from the FDA. 

• Experienced Leadership: The company has strengthened its team by bringing in executives from Amryt Pharma, a rare disease specialist previously acquired for €1.48 billion. 

• Financial Health: As of June 30, 2024, Poolbeg reported a cash balance of £10.1 million, indicating robust financial management. 

ImmuPharma (IMM):

• Lead Candidate: P140 (Lupuzor™) is in Phase 3 trials for Systemic Lupus Erythematosus (SLE) and has shown promise in treating autoimmune diseases. 

• Partnerships: The company has an exclusive license and development agreement with Avion Pharmaceuticals for Lupuzor™ in the U.S. 

• Recent Funding: In February 2025, ImmuPharma secured £2.91 million through an oversubscribed investment round to support the development of P140. 

• Ongoing Discussions: ImmuPharma has been in discussions with global biopharmaceutical companies regarding potential licensing deals for P140.

Assessment:

While both companies have promising assets, Poolbeg Pharma appears to be better positioned for a potential buyout in the near term. The combination of advanced-stage assets with significant market potential, strategic acquisitions, experienced leadership, and strong financial health makes Poolbeg an attractive candidate for acquisition. ImmuPharma, while progressing with its lead candidate and engaging in partnership discussions, may require further clinical validation and financial strengthening to be equally positioned for a buyout.

The recent FDA Orphan Drug Designation (ODD) granted to Poolbeg Pharma’s lead candidate, POLB 001, is a significant milestone. This designation not only underscores the potential of POLB 001 in addressing a critical unmet medical need but also enhances its commercial appeal to prospective partners. The ODD status offers benefits such as seven years of market exclusivity in the U.S. upon regulatory approval, potential waiver of application fees, and eligibility for tax credits related to clinical trial costs.

When comparing Poolbeg Pharma (LSE: POLB) and ImmuPharma (LSE: IMM) regarding their positioning for a potential buyout, several factors come into play:

Poolbeg Pharma (POLB):

• Advanced Pipeline: POLB 001 is a Phase 2-ready candidate targeting Cytokine Release Syndrome (CRS), with a potential market opportunity of approximately $10 billion. 

• Strategic Acquisitions: Poolbeg has secured an exclusive 12-month option to acquire tPTX, a treatment for Behçet’s Disease, which has both Orphan Drug and Fast Track Designations from the FDA. 

• Experienced Leadership: The company has strengthened its team by bringing in executives from Amryt Pharma, a rare disease specialist previously acquired for €1.48 billion. 

• Financial Health: As of June 30, 2024, Poolbeg reported a cash balance of £10.1 million, indicating robust financial management. 

ImmuPharma (IMM):

• Lead Candidate: P140 (Lupuzor™) is in Phase 3 trials for Systemic Lupus Erythematosus (SLE) and has shown promise in treating autoimmune diseases. 

• Partnerships: The company has an exclusive license and development agreement with Avion Pharmaceuticals for Lupuzor™ in the U.S. 

• Recent Funding: In February 2025, ImmuPharma secured £2.91 million through an oversubscribed investment round to support the development of P140. 

• Ongoing Discussions: ImmuPharma has been in discussions with global biopharmaceutical companies regarding potential licensing deals for P140.

Assessment:

While both companies have promising assets, Poolbeg Pharma appears to be better positioned for a potential buyout in the near term. The combination of advanced-stage assets with significant market potential, strategic acquisitions, experienced leadership, and strong financial health makes Poolbeg an attractive candidate for acquisition. ImmuPharma, while progressing with its lead candidate and engaging in partnership discussions, may require further clinical validation and financial strengthening to be equally positioned for a buyout.

This is big news , just joined the party ..

Great RNS , the reason I invested at the recent dip , knew its was on its way .. My only concern is this should be over a Penny plus now .. what is going on here .. ??

Warrie I can assure you I wont be selling a beam now .. or in weeks to come .. this one is a keeper as they say old chap ....

It seems as soon as we hit 72 , a sell goes through , or are they buys reported in black .. the think is they are big numbers.

Guys the only reason I stood by sold out and then bought bakc in was I knew the discussions were advanced yet also knew from deep research it would take some time to conclude .

It has now been 6 weeks from the 13 April since we was advised abundantly about the advanced discussions with R42 group , which is the very reason I jumped back in on the dip which quite frankly would of still bought back in even if it was still rising without news as I know news now is imminent, and we could receive this news any minute now .

R42 isn’t just any VC – they’ve backed some of the most exciting early-stage tech and biotech companies. With 89+ investments and a portfolio that includes multimillion-dollar rounds (Healx raised $47M in one!), their track record speaks volumes.

Now imagine what this kind of backing could mean for CPAI…

Let’s talk potential:

• Massive credibility boost: An alliance with R42 would validate CPAI’s tech and strategy. Investors love this kind of strategic tie-up.

• Money + Minds: R42 brings not only capital but deep expertise in AI and life sciences – this could seriously supercharge CPAI’s growth.

• Share Price Catalyst? If the alliance is finalized, don’t be surprised to see a strong upward move in CPAI’s share price. We’re talking potential doubling or more depending on the structure of the deal and the market response. The market reacts fast to momentum and credibility – and this has both written all over it.

We’ve seen how strategic partnerships have sent other small-cap tech stocks flying – this one has all the ingredients for a similar move.

Keep your eyes locked on CPAI – this could be the start of something huge.

DYOR but stay ready.

I see a strong close , 0.80 .... that is what the graphs are saying lets see ..

Silver light , 2 p can come here , its not impossible .. no doubt we would need exceptional news and some serious player to buy us out or JV ...